New breakthroughs in adult stem cell technology offer staggering implications for medical science, says Patrick Cox. And a massive opportunity for investors. As Big Pharma move in, Patrick says biotech companies involved in stem cell research and RNA technology could become the “investment of a lifetime.”

As major Wall Street players disappear down the toilet and the government’s bailouts rumble on, Breakthrough Technology Alert editor Patrick Cox says investors can find exciting developments in chip technology and robotics. These transformative industries can yield mega profits, especially given the growth potential of robots in the manufacturing and defense industries.

Greetings once again. I hope you’re having a good week. There are just a few things I’d like to deal with today. One is the persistent pessimism I’m seeing in both the media and the polls. I just looked at Gallup’s daily numbers, and the phenomenon is clear. More than three-quarters of Americans believe we are in some sort of recession. 40% believe their standard of living will decline in the future. Almost a third believe the next generation will be worse off than this one.

I’d like to tell you about a couple of important new breakthroughs that have just shown up on the radar. Both have enormous potential, in terms of both your health and your portfolio.

The coming together of nanotech and biotech could resurrect the pharmaceutical market, says Patrick Cox in Penny Sleuth.

By using nanotech structures to modify existing drugs, small-cap pharma companies can sidestep the hefty costs and risks of new drug approval. This has traditionally been a major barrier to entry for start-ups. More importantly, early research has shown the altered drugs to be extremely effective against a broad range of serious diseases.

As new ventures approach IPO, they will create great investment opportunities. More from Patrick…

Is it finally time to invest in stem-cell technology? Tech junkie Patrick Cox, writing in Penny Sleuth, thinks so.

The FDA recently banned stem cell company Geron Corporation (NASDAQ:GERN) from going ahead with trials of its spinal-cord therapy. But great transformational investors have always bought when the public has given up hope on new technologies.

It now looks like there might be a breakthrough in heart failure prevention, says Patrick. Although they won’t go on the record about it yet, leading researchers expect a breakthrough to occur in the next five years…